<DOC>
	<DOCNO>NCT00072137</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vaccine therapy give directly bladder treat patient undergo surgery remove part bladder . Vaccines make gene-modified virus may help body build effective immune response kill tumor cell . Giving vaccine directly bladder surgery may cause strong immune response keep tumor cell come back surgery .</brief_summary>
	<brief_title>Neoadjuvant Intravesical Vaccine Therapy Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety intravesical administration recombinant fowlpox virus encode three different costimulatory molecule ( B7.1 , ICAM-1 , LFA-3 ) call TRICOM ( -rF-TRICOM ) ( recombinant fowlpox-TRICOM vaccine ) and/or recombinant fowlpox encode sargramostim ( GM-CSF ) ( rF-GM-CSF ) ( recombinant fowlpox GM-CSF vaccine adjuvant ) treatment patient carcinoma bladder schedule cystectomy . SECONDARY OBJECTIVES : I . Determine kinetics viral infection gene function well host response intravesical recombinant fowlpox virus treatment bladder cancer . OUTLINE : This dose-escalation study . Patients alternately assign Arms A B . Once Arms A B finish accrual , patient assign Arm C. ARM A ( closed accrual 10/2004 ) : Patients receive recombinant fowlpox GM-CSF vaccine adjuvant intravesically 2 hour 4 weekly dos ( day 1 , 8 , 15 , 22 ) last dose give 4-6 day prior cystectomy . ARM B ( close accrual 10/2004 ) : Patients receive recombinant fowlpox-TRICOM vaccine intravesically 2 hour 4 weekly dos ( day 1 , 8 , 15 , 22 ) last dose give 4-6 day prior cystectomy . ARM C : Patients receive recombinant fowlpox-TRICOM vaccine combine recombinant fowlpox GM-CSF vaccine adjuvant intravesically 2 hour 4 weekly dos ( day 1 , 8 , 15 , 22 ) last dose give 4-6 day prior cystectomy . In arm , treatment continue absence disease progression unacceptable toxicity . All patient undergo cystectomy 4-6 day follow last intravesical instillation . After completion study treatment , patient follow every 6 month 2 year annually 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Patients must histologically document bladder cancer include : transitional cell carcinoma , adenocarcinoma , squamous cell carcinoma include carcinoma situ ( CIS ) require cystectomy standard therapy his/her tumor stage schedule surgical procedure ; patient candidate neoadjuvant chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Estimated life expectancy 6 month Prior therapy intravesical Bacille CalmetteGuerin ( BCG ) and/or chemotherapy allow ; patient must least 2 month beyond instillation prior intravesical agent ; patient receive systemic chemotherapy , radiation therapy , immunotherapy systemic dos steroid least 4 week prior start vaccination recover acute toxicity previous treatment ; patient receive neoadjuvant chemotherapy radiation therapy bladder ineligible study Serum creatinine &lt; 1.5 mg/dl creatinine clearance &gt; 60 ml/min Bilirubin &lt; 2.0 mg/dl Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 x normal range Absolute neutrophil count ( ANC ) &gt; 1500/mm^3 Platelets &gt; 75000/mm^3 Patients must know immunodeficiency disorder ( acquired immunodeficiency syndrome [ AIDS ] , severe combine immunodeficiency [ SCID ] , WiskottAldrich syndrome , etc . ) ; study candidate specifically screen , unless clinically indicate ; indicate , refer physician evaluation No active/uncontrolled infection Pregnant woman nurse mother ineligible ; woman reproductive potential must negative pregnancy test prohibit sexual intercourse study ( receive vaccine least 1 month follow last dose ) ; sexual abstinence ( opposed contraception ) necessary ; similarly , male patient also must avoid sex period No uncontrolled psychiatric illness medical illness principal investigator feel compromise patient 's tolerance study treatment Patients must inform investigational nature study must give write informed consent accordance institutional federal guideline ; patient provide informed consent eligible study Altered immunecompetence : Current imminent steroid therapy active antibiotic therapy ( antibiotic give prophylaxis allow ) Immune deficiency disease immunosuppressive therapy patient Present history autoimmune disease patient ( e.g . autoimmune neutropenia , thrombocytopenia , hemolytic anemia ; systemic lupus erythematosus , Sjogren syndrome , scleroderma ; myasthenia gravis ; Goodpasture syndrome ; Addison 's disease , Hashimoto 's thyroiditis , active Graves ' disease , diseases qualify autoimmune origin ) History allergy egg vaccine manufacture chicken embryo cell Patients presence liver function abnormality , exposure toxin , ongoing alcohol consumption , history liver disease and/or history hepatitis may suggest persistent disease Any concurrent active second malignancy malignant tumor within prior 5 year exception superficial squamous basal cell skin carcinoma situ carcinoma cervix prostate Pregnancy Patients active ischemic heart disease ( i.e . class III IV cardiac diseaseNew York Heart Association ) , recent history myocardial infarction ( within last 6 month ) , history congestive heart failure , ventricular arrhythmia arrhythmia require therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>